Dexamethasone, all trans retinoic acid and interferon alpha 2a in patients with refractory multiple myeloma.

Abstract	Few effective regimen are available for patients with refractory multiple myeloma (RMM). Generally, responses are scarce and disease free survival is very short. We developed a new therapeutic option in these patients using dexamethasone (40 mg/m2, i.v., daily, days 1 to 4), all-trans retinoic acid (45 mg/m2, po, daily, days 5 to 14) and interferon alpha 2a (9.0 MU, daily, subcutaneously, days 5 to 14). The treatment was administered every 21 days for 6 cycles. In a pilot study, 12 patients, heavily treated with chemotherapy and radiotherapy and in some cases with interferon, were allocated to receive the afore mentioned treatment. Response was observed in 10 patients (83%). With a median follow-up of 36.1 months (range 27 to 41), seven patients remain alive and disease-free without any treatment. Two patients were failures and have died due to tumor progression. Toxicity was mild and all patients received treatment according to the planned doses of drugs. The use of biological modifiers in combination with dexamethasone offer a safe and effective therapeutic option in patients with refractory multiple myeloma. More studies are warranted to define the role of this type of treatment.
Authors	A Avilés, A Rosas, J Huerta-Guzmán, A Talavera, S Cleto
Journal	Cancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 14 Issue 1 Pg. 23-6 (Feb 1999) ISSN: 1084-9785 [Print] United States
PMID	10850283 (Publication Type: Clinical Trial, Journal Article)
Chemical References	Antineoplastic Agents, Hormonal Immunologic Factors Interferon alpha-2 Interferon-alpha Recombinant Proteins Tretinoin Dexamethasone
Topics	Adult Aged Antineoplastic Agents, Hormonal (adverse effects, therapeutic use) Combined Modality Therapy Dexamethasone (adverse effects, therapeutic use) Disease-Free Survival Female Follow-Up Studies Humans Hyperglycemia (chemically induced) Immunologic Factors (therapeutic use) Interferon alpha-2 Interferon-alpha (therapeutic use) Male Middle Aged Multiple Myeloma (drug therapy, therapy) Pilot Projects Recombinant Proteins Treatment Outcome Tretinoin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!